What factors drove the changes in Lantern Pharma's revenue and profit?

What were the key takeaways from Lantern Pharma’s earnings call?

Did Lantern Pharma beat or miss consensus estimates last quarter?

What does Lantern Pharma do and what are its main business segments?

What is the market's earnings forecast for Lantern Pharma next quarter?

What guidance did Lantern Pharma's management provide for the next earnings period?

What is Lantern Pharma's latest dividend and current dividend yield?

What were the key takeaways from Lantern Pharma's earnings call?

- **Clinical Success**: LP-184 Phase Ia shows 48% clinical benefit rate; LP-300 achieves 86% response rate in never-smokers.
- **AI Breakthrough**: RADR modules deliver 94% BBB permeability accuracy; withZeta enables rapid rare cancer drug discovery.
- **Cash Runway**: $12.4M supports operations into Q3 2026; $1.6M raised via ATM in Q3.
- **Strategic Growth**: $7B+ addressable market for LP-184 trials; Zeta to transform rare cancer R&D with 500K+ trial insights.

**【CEO Summary Section】**
- **Clinical Milestones**: LP-184 Phase Ia trial achieved a 48% clinical benefit rate in evaluable patients, with notable tumor reductions in DNA damage repair mutation carriers. LP-300 showed an 86% clinical benefit rate in never-smoker lung cancer, including a 2-year complete response.
- **Pipeline Expansion**: LP-184 advancing into 4 Phase Ib/II trials targeting $7B+ market (triple-negative breast, NSCLC, bladder, GBM). LP-284 demonstrates complete responses in recurrent lymphomas and potential in autoimmune diseases.
- **AI Commercialization**: RADR AI modules (PredictBBB, LBx-AI) achieve 94% and 86-90% accuracy, with $1B+ market potential. New withZeta platform for rare cancer drug discovery launched, enabling rapid insights across 500K+ trials and 1.2M+ data points.
- **Operational Efficiency**: Transitioned CRO services in Asia to reduce costs, maintaining $12.4M cash runway into Q3 2026.

**【CFO Financial Commentary】**
- **Q3 2025 Financials**: Net loss of $4.2M ($0.39/share), down 7% YoY. R&D expenses decreased 35% to $2.4M, G&A up 27% to $1.9M due to business development. Cash position of $12.4M supports operations into mid-2026.
- **Funding Updates**: Sold $1.6M in ATM shares Q3, with $634K raised post-quarter. Fully diluted shares: ~12.26M.

**【Q&A Highlights】**
- **Clinical Trial Timelines**: LP-300 interim data webinar in December; Denmark bladder cancer trial启动 late Dec/early Jan. IND submission for pediatric CNS trial expected soon.
- **Partnership Opportunities**: Interest from pharma companies in LP-184 Phase Ib/II trials; withZeta demos to partners in Q1 2026.
- **AI Platform Expansion**: Zeta已内部使用，计划Q1 2026全面推出，可加速罕见癌药物开发周期数月。


Lantern Pharma Inc. (LTRN) Q3 2025 Earnings Call Transcript

- **Clinical Momentum**: LP-184 Phase 1a nearing completion with 62-65 patients, supported by dual Fast Track designations. Early data aligns with preclinical potency, positioning for TNBC and CNS indications.
- **AI Breakthroughs**: Radar AI's BBB permeability module achieves 98% accuracy, reducing discovery timelines by 30-50%. ADC module slashes preclinical costs by 66%, opening new partnership opportunities.
- **Financial Strength**: $19.7 million cash runway through mid-2026. Net loss down 17% YoY to $4.5 million, with no dilutive funding required.
- **Strategic Growth**: Pursuing partnerships for LP-184 in high-value indications, while monetizing AI modules via freemium model to diversify revenue.

**【CEO Opening Remarks】**
- **Clinical Pipeline Progress**: Phase 1a trial for LP-184 nearing completion with 62-65 patients enrolled across solid tumors. FDA granted dual Fast Track designations for glioblastoma and triple-negative breast cancer (TNBC), plus four rare pediatric disease designations. Early pharmacokinetic data align with preclinical potency, signaling potential proof of mechanism.
- **AI Platform Expansion**: Radar AI platform now includes 200 billion oncology data points. Key advancements include a blood-brain barrier (BBB) permeability prediction module with 98% accuracy and an AI-powered antibody drug conjugate (ADC) development module. These tools aim to reduce discovery timelines by 30-50% and preclinical costs by 66%.
- **Shareholder Value Initiatives**: Maintained $19.7 million cash runway through mid-2026. Seeking partnerships for LP-184 in TNBC and drug-resistant NSCLC, leveraging Fast Track status for accelerated development. Exploring commercialization of AI modules via a freemium model to generate new revenue streams.

**【CFO Financial Highlights】**
- **Q1 2025 Financials**: Net loss of $4.5 million ($0.42 per share), down 17% year-over-year. R&D expenses decreased 23% to $3.3 million due to optimized clinical operations. Cash reserves of $19.7 million support operations for at least 12 months. No dilutive funding required through mid-2026.
- **Operational Efficiency**: Reduced G&A expenses by 2% to $1.51 million. Last capital raise in Jan 2021; no equity financing since, demonstrating disciplined capital stewardship.

**【Q&A Key Takeaways】**
- **AI Commercialization Strategy**: Launching BBB permeability module first via freemium access, with plans to expand to ADC and CNS-focused tools. Agnostic to collaboration type (licenses, co-development, or open-source contributions).
- **Clinical Trial Milestones**: LP-184 Phase 1a enrollment completes in June 2025, with initial data readouts by Q3. Harmonic trial expansion cohort (U.S. and Asian patients) expected to report results in Q3, including Asian subset analysis.
- **FDA & AI Adoption**: Anticipate FDA adoption of AI for regulatory reviews within 1-2 years, driven by cost and speed benefits. Early parallel testing with traditional methods likely to mitigate risks.

Lantern Pharma Inc. (LTRN) Q1 2025 Earnings Call Transcript

- **Clinical Success with AI Drugs**: LP-300 achieves 86% clinical benefit in never-smoker NSCLC, with Asian expansion driving 3-4x faster enrollment. LP-184 Phase I nearing completion, no safety issues at dose level 0.61 mg/kg.
- **Breakthrough CNS Therapy**: STAR-001 eliminates GBM in preclinical models, with 90%+ accurate AI predicting blood-brain barrier penetration.
- **Financial Sustainability**: $24M cash runway for 2025, but additional funding needed for growth. AI-driven R&D costs 80% less than industry average.
- **Global Expansion Strategy**: 30%+ NSCLC never-smokers in Japan/Taiwan vs. 15% U.S. Drives faster data readouts and potential partnerships.

**【CEO Summary Section】**
- **AI-Driven Drug Development Progress**: 3 AI-derived drug candidates (LP-300, LP-184, LP-284) in Phase I/II trials, with LP-300 showing an 86% clinical benefit rate in never-smoker NSCLC patients. Expansion into Japan and Taiwan accelerates enrollment, targeting mid-2025 data readouts.
- **Clinical Milestones**: LP-184 Phase I trial nearing completion with 50+ patients enrolled, no serious adverse events. LP-284 Phase I expected to complete later this year. FDA Fast Track designations for LP-184 in glioblastoma and triple-negative breast cancer validate regulatory strategy.
- **Innovative Trial Design**: STAR-001 (Starlight Therapeutics) combines spironolactone and synthetic lethality to target GBM, showing complete tumor eradication in preclinical models. Blood-brain barrier AI algorithm achieves 90%+ accuracy, enabling rapid CNS drug discovery.
- **Partnerships & Global Expansion**: Collaborations with Nigerian and Danish institutions for TNBC and bladder cancer trials. Asian enrollment pace 3-4x faster than U.S., leveraging higher never-smoker NSCLC incidence (30-40% vs. 15%).

**【CFO Financial Commentary】**
- **Q4 2024 Financials**: Net loss of $5.9M ($0.54/share), up 40% YoY. R&D expenses $4.3M (19% YoY increase), driven by clinical trial costs. Full-year 2024 cash balance $24M, providing 12+ months runway. Need additional funding for 2025 expansion.
- **Burn Rate Efficiency**: $2-2.5M per drug candidate development vs. industry average $10-15M. 2024 R&D/G&A ratio 2.6x, reflecting focus on pipeline advancement.

**【Q&A Highlights】**
- **Asian Enrollment**: Asian sites achieve 3-4x faster enrollment than U.S., with Japan/Taiwan contributing 25% of HARMONIC trial patients.
- **ADC Development**: AI-identified 82 targets, 290+ indication combinations. Preclinical data shows 100-500x potency vs. approved agents. Partnerships with biotechs to leverage ADC AI module expected Q2 2025.
- **STAR-001 Pediatric Pathway**: Protocol with POETIC consortium for pediatric glioma trials, leveraging rare pediatric disease designations. First patients expected mid-2025.

Actual	-0.31	-0.27	-0.47	-0.24	-0.21	-0.36	-0.31	-0.38	-0.41	-0.21	-0.31	-0.36	-0.44	-0.29	-0.39	-0.51	-0.46	-0.42	-0.54	-0.42	-0.4	-0.39
Forecast	-0.31	-0.3333	-0.4533	-0.27	-0.255	-0.2667	-0.4033	-0.29	-0.52	-0.48	-0.47	-0.48	-0.4333	-0.4833	-0.4	-0.43	-0.55	-0.56	-0.51	-0.49	-0.44	-0.47	-0.46
Surprise	0.00%	+18.99%	-3.68%	+11.11%	+17.65%	-34.98%	+23.13%	-31.03%	+21.15%	+56.25%	+34.04%	+25.00%	-1.55%	+40.00%	+2.50%	-18.60%	+16.36%	+25.00%	-5.88%	+14.29%	+9.09%	+17.02%	0.00%

Actual	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	--
Forecast	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

LTRN

LTRN fundamentals

LTRN Q4 2025 Earnings Preview

Earnings Call

You can ask Aime

LTRN

LTRN fundamentals

LTRN Q4 2025 Earnings Preview

Earnings Call

LTRN Earnings Call Summary for Q4/2025Upcoming4:30 PM on Mar 30, 2026

LTRN Earnings Call Summary for Q3/20259:00 AM on Nov 13, 2025

LTRN Earnings Call Summary for Q2/20254:30 PM on Aug 14, 2025

LTRN Earnings Call Summary for Q1/20259:00 AM on May 15, 2025

LTRN Earnings Call Summary for Q4/20244:30 PM on Mar 27, 2025

You can ask Aime